Pancreatic Cancer
Conditions
Keywords
irreversible electroporation, pancreatic cancer
Brief summary
Pancreatic cancers is one the most important malignancies with highest mortality in the world. The prognosis of these patients is very poor. Although some patients with early-diagnosed disease could receive surgical intervention, a majority (70%to 80%) of patients present with locally advanced or metastatic status are inoperable. Patients in this late status usually are recommended to receive palliative bypass operation such as choledochojejunostomy and/or gastrojejunostomy and palliative radiotherapy for the pancreatic cancer. Radiofrequency ablation (RFA) used to be expected an alternative therapy. However, the main drawback of RFA is its side effect to damage adjacent structure such as bile duct, and the tumors located adjacent to vessels could not be ablated well.
Detailed description
Irreversible electroporation (IRE), developed and manufactured by AngioDynamics US Ltd, can ablate tumor by fenestrating the cancer cell membrane by electric pulse. The anti-tumor effect does not result from thermotherapy, so is also not diminished by adjacent vessels. Several pre-clinical and clinical studies have already demonstrated IRE is a safe and effective treatment, and the adjacent tissue such as vessels and ductal structures will be spared. Recently, IRE had been used to treat pancreatic cancer successfully, and the safety is satisfactory. The system has been approved as safe by the European Union (EU) in 2008 and received Food and Drug Administration (FDA) approval in 2010. However, there are still few experiences in using IRE for tumor ablation in Taiwan. In this study, the investigators will perform IRE for inoperable patients with locally advanced pancreatic cancers. They will receive IRE during the operation of palliative bypass operation including choledochojejunostomy and/or gastrojejunostomy. The investigators will evaluate the potential side effect and ablate effect of tumors, and also follow-up the patients for 2 years to evaluate the overall survival. The investigators will appraisal the clinical feasibility and advantage of the system by this study.
Interventions
Sponsors
National Taiwan University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Patients must meet all of the following inclusion criteria to be eligible for this study: 1. Locally advanced pancreatic cancer is defined as per the 7th edition of the American Joint Committee on Cancer (AJCC) staging system for pancreatic cancer -described as arterial encasement of either the celiac axis or superior mesenteric artery or both. 2. Biliary tract or intestine is compromised by tumor, palliative bypass operation (hepaticojejunostomy and/or gastrojejunostomy) is considered to be performed. 3. Eastern Cooperative Oncology Group (ECOG) score of 0-1, 4. American Society of Anaesthesiologists (ASA) score ≤ 3, 5. Adequate bone marrow, liver and renal function. Platelet count ≥ 100 K/Μl. Total bilirubin ≦ 5 mg/dL. alanine transaminase (ALT) and aspartate transaminase (AST) \< 5 x upper limit of normal. prothrombin time (PT)- international normalized ratio (INR) ≦ 2.0 (5). Serum creatinine ≦ 1.5 x upper limit of normal 6. Prior Informed Consent Form 7. Life expectancy of at least 3 months.
Exclusion criteria
Patients presenting with any of the following will not be enrolled into this study: 1. History of cardiac disease: 2. Congestive heart failure \>New York Heart Association (NYHA) class 2 3. Active coronary artery disease (CAD) (myocardial infarction more than 6 months prior to study entry is allowed) 4. Cardiac arrhythmias (\>Grade 2 NCI-CTCAE Version 3.0) which are poorly controlled with anti-arrhythmic therapy or requiring pace maker 5. Uncontrolled hypertension 6. Any active metal implanted device (eg Pacemaker), 7. Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception, 8. Received treatment with an investigational agent/ procedure within 30 days prior to treatment with the IRE System, 9. Known history of human immunodeficiency virus (HIV) infection 10. Patients with resectable lesions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor response | 1 month after treatment | Tumor response will be evaluated by abdominal computed tomography (CT) or magnetic resonance imaging (MRI). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Haematology test | one to two years | complete white blood cell count with differential, red blood cell count, hemoglobin, hematocrit, and platelets |
| Tumor marker measurement | one to two years | measure the change of tumor marker such as carcinoembryonic antigen (CEA) |
| Eastern Cooperative Oncology Group (ECOG) evaluation | one to two years | Complete an Eastern Cooperative Oncology Group (ECOG) evaluation |
| Review concomitant medications | one to two years | Use of medications will be reviewed and recorded |
| Assess for presence of adverse event | one to two years | An adverse event assessment will be performed |
| Conduct computed tomography (CT) or magnetic resonance imaging (MRI) scans for tumour response evaluation | one to two years | Subjects will still be followed-up in the event of disease progression in order to document overall survival, a secondary endpoint. |
Outcome results
None listed